LENZ Therapeutics, Inc. (LENZ) Misses Q2 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
LENZ Therapeutics Inc (LENZ) PT Lowered to $32 at Citi
August 15, 2024 4:58 AM EDTCiti analyst Yigal Nochomovitz lowered the price target on LENZ Therapeutics Inc (NASDAQ: LENZ) to $32.00 (from $34.00) while maintaining a Buy rating.
The analyst comments "LENZ continues to execute very effectively on pre-commercialization plans for LNZ100 in presbyopia. While there was not... More
